Peptide Testing Explained: Identity, Purity, Quantity, Sterility, Endotoxin, and COAs

Short answer: “Tested” is not a complete quality claim. Peptide identity, chromatographic purity, peptide quantity, sterility, and bacterial endotoxin are different attributes. Each requires an appropriate method, a traceable sample, and a result that is reported on a clearly defined basis.

This guide is an evidence-literacy resource. It does not evaluate whether a product is safe, effective, lawful, or suitable for human use.

The five questions peptide tests can answer

Question | Common evidence | What the result can support | What it does not establish by itself

Is the expected peptide present? | LC-MS, MS/MS, amino-acid or sequence-sensitive methods | Identity evidence consistent with the target analyte | Amount, sterility, endotoxin, clinical safety, or complete structural characterization

How much related material was separated from the main peak? | RP-HPLC or UPLC with a stated detector and calculation | Chromatographic purity or impurity profile under that method | Net peptide content by mass, identity of every peak, or absence of undetected impurities

How much peptide is in the sample or vial? | A validated assay against a characterized standard, amino-acid analysis, qNMR, or mass-balance-supported assignment | Peptide content or amount on the stated basis | Sterility, endotoxin, or biological activity

Did the tested sample show microbial growth under the stated procedure? | Sterility test | Result for the tested units and conditions | Guaranteed sterility of every vial, process validation, or endotoxin status

What level of bacterial endotoxin was detected? | Bacterial endotoxins test with controls and a stated limit | Endotoxin result for the tested sample | Sterility, absence of all pyrogens, or overall safety

The ICH Q2(R2) guideline frames analytical validation around a simple principle: a procedure should be fit for its intended purpose. The test name therefore matters less than the question the procedure was designed, performed, and reported to answer.

A practical evidence stack

A useful peptide report can be read as six layers. Missing layers do not automatically make a result false, but they limit what an outside reader can verify.

1. Traceability

The report should connect the result to a defined sample. Look for the product name, vendor or submitting party, lot or batch number, laboratory sample identifier, receipt date, test date, and report date. A result that cannot be matched to the offered lot is weak evidence for that lot.

Traceability also has a time dimension. A report from an earlier batch may describe historical performance, but it should not be silently presented as evidence for a current batch.

2. Identity

Identity testing asks whether the expected analyte is present. Mass spectrometry can compare observed mass-to-charge data with the expected molecule; tandem mass spectrometry can provide additional sequence-related evidence. Other orthogonal techniques may be needed where closely related structures, isomers, chirality, or modifications are important.

The peptide-reference-standard literature describes using multiple techniques, including mass spectrometry, chromatography, NMR, amino-acid analysis, and chiral testing, to establish different parts of identity and characterization. That does not mean every routine retail report needs every technique. It does mean that a single matching number should not be expanded into a claim the method was not designed to prove. See Reference Standards to Support Quality of Synthetic Peptide Therapeutics.

3. Chromatographic purity

Reversed-phase HPLC commonly separates a main peptide peak from detectable related peaks under a specified set of conditions. Reports often express the main peak as a percentage of total integrated detector response.

That value is method-dependent. Column chemistry, mobile phase, gradient, detector wavelength, integration rules, sample concentration, and co-elution can affect what is separated or counted. A reported “99% HPLC purity” is best read as a chromatographic-area result under the stated method, not as a universal statement that 99% of the vial’s total mass is the target peptide.

This distinction is central. The USP-affiliated peptide-reference-standard paper separates HPLC-related impurities from water, counterions, residual solvents, and other material when assigning bulk purity by mass balance. A synthetic-glucagon study likewise measured water, trifluoroacetic acid, inorganic ions, and peptide-related impurities separately before assigning mass fraction. See Purity determination of synthetic glucagon using a mass balance approach.

4. Peptide quantity or content

Quantity asks how much peptide is attributable to the sample or vial on a defined basis. That is not automatically answered by an HPLC area percentage.

Quantitative approaches can include an assay against a well-characterized reference standard, amino-acid analysis, quantitative NMR, or a mass-balance-supported assignment. Each has assumptions and uncertainty. A useful report should state the unit, calculation basis, reference material, and whether the value represents peptide, peptide salt, dry mass, or another defined quantity.

If a vial is labeled with a nominal amount but the report only provides retention time, molecular mass, and area percent, the amount claim remains unverified by that report.

5. Sterility

Sterility testing asks whether viable microorganisms are detected in the tested units under the procedure. It is a microbiological test, not a chemical-purity test.

Sampling matters. Testing a subset cannot provide absolute certainty about every unit, and a sterility result does not replace evidence about how a purportedly sterile product was manufactured and controlled. FDA’s aseptic-processing guidance treats testing as one component of a broader control system for sterile drug products.

6. Bacterial endotoxin

Bacterial endotoxins are lipopolysaccharides associated with gram-negative bacteria. An endotoxin test addresses a different hazard from viable microbial contamination. A sample can have a sterility result without an endotoxin result, or the reverse.

The report should identify the method, result units, applicable limit, dilution, and controls for interference where relevant. FDA’s Pyrogen and Endotoxins Testing Q&A notes that the physical and chemical properties of a test article can interfere with bacterial endotoxins assays. “Endotoxin tested” is therefore incomplete without the result and method context.

Original analysis: the claim-to-test map

PeptidesReview.org will evaluate a testing claim by matching the wording of the claim to the evidence actually present.

Claim shown to a reader | Minimum evidence we would look for | Evidence gap if absent

“Identity confirmed” | Target analyte, observed result, expected result, method, and interpretable MS or other identity evidence | A purity chromatogram alone may not establish identity

“99% pure” | Definition of purity, method, detector, integration basis, and result tied to a lot | It may be unclear whether this means area percent or mass fraction

“Contains 10 mg” | Quantitative method, reference basis, units, result, and uncertainty or acceptance criteria where available | Identity and area percent do not verify vial content

“Sterile” | Sterility method, sample/lot, dates, result, and sampling context | Chemical testing does not address viable microorganisms

“Low endotoxin” | Bacterial endotoxins method, units, limit, controls, and lot-specific result | Sterility does not imply low endotoxin

“Third-party tested” | Named laboratory, sample identity, submitter or sampling disclosure, signed/final report, and verification path | Outsourcing alone does not establish independence or chain of custody

This map prevents a common reasoning error: allowing one test to inherit the authority of an entire quality conclusion.

What makes an analytical procedure credible?

A polished report is not the same as a suitable method. For quantitative and limit tests, readers should look for enough information to understand specificity or selectivity, accuracy, precision, range, detection or quantitation limits where relevant, and system suitability.

The level of documentation varies by context. PeptidesReview.org will not claim that an unregulated report complies with pharmaceutical requirements unless the evidence supports that statement. We use FDA analytical-method guidance and ICH Q2(R2) as benchmarks for understanding what makes a procedure scientifically interpretable, not as proof that every tested research sample is a regulated drug product.

How to read “third-party tested”

“Third-party” can mean only that a different company performed the test. It does not, by itself, reveal who selected the sample, whether the laboratory received it directly from retail inventory, whether the vendor chose a favorable report, or whether the posted file is complete and current.

For each report, we will distinguish:

• Vendor-submitted testing: the vendor selected or supplied the sample.
• Retail-sampled testing: an identified party obtained the sample through an ordinary transaction.
• Independently commissioned testing: an editorial or other independent party controlled sampling and submission.
• Unknown chain of custody: the public record does not disclose enough to classify the path.

These labels describe provenance. They are not automatic judgments about whether a laboratory result is accurate.

A stronger peptide testing package

No universal checklist fits every peptide or use. For transparent public evidence, however, a stronger package generally includes:

1. A final report from a named laboratory.
2. A laboratory sample ID and vendor lot or batch match.
3. Receipt, test, and report dates.
4. The exact analyte and sample form.
5. A clearly named method for each result.
6. Identity evidence that is separate from chromatographic purity.
7. A defined calculation basis for any purity percentage.
8. A quantitative assay if an amount-per-vial claim is made.
9. Sterility and endotoxin results only when those attributes are claimed.
10. Chromatograms, spectra, or other supporting output where the laboratory provides them.
11. Method suitability, acceptance criteria, or validation context sufficient to interpret the result.
12. A laboratory-hosted verification link, report identifier, digital signature, or other authenticity control.

Limitations

• This guide explains analytical evidence; it is not a specification for any particular product.
• Pharmaceutical guidance and reference-standard practices provide scientific benchmarks but may not be legal requirements for every research product or laboratory.
• Public reports may omit method-validation, sampling, raw-data, or uncertainty information that the laboratory holds privately.
• Results apply to the tested sample and stated conditions. They should not be generalized automatically to every vial, batch, vendor, or later date.
• Peptide-specific attributes can require techniques not covered in this overview.

What this does not prove

A COA or laboratory result does not, by itself, prove that a peptide is safe, effective, approved, legally marketed, manufactured under appropriate controls, or suitable for human use. It also does not prove that the submitted sample represents ordinary retail inventory or that future lots will perform the same way.

PeptidesReview.org will report what a document supports, what remains unknown, and when the evidence was last reviewed. We will not convert analytical results into medical advice or purchase recommendations.